Quarterly report pursuant to Section 13 or 15(d)

Inventory

v3.21.1
Inventory
3 Months Ended
Mar. 31, 2021
Inventory Disclosure [Abstract]  
Inventory

Note 6:

Inventory

Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. The Company expensed costs related to inventory within the Research and development line in the Consolidated Statements of Operations until it received approval from the FDA to market a product, at which time the Company commenced capitalization of costs relating to that product. Adjustments to inventory are determined at the raw material, sub-assemblies and finished goods levels to reflect obsolescence or impaired balances.

Inventory was as follows:

 

 

 

March 31, 2021

 

 

December 31, 2020

 

Raw materials

 

$

68

 

 

$

130

 

Sub-assemblies

 

 

2,482

 

 

 

2,476

 

Finished goods

 

 

788

 

 

 

928

 

 

 

 

3,338

 

 

 

3,534

 

Provision for inventory obsolescence

 

 

(565

)

 

 

(556

)

 

 

$

2,773

 

 

$

2,978